Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures
Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms
Read More 6 minute read Pharma Industry News From rare disease to mass market: plozasiran gets FDA green light for severe hypertriglyceridemia review Arrowhead’s plozasiran receives FDA Breakthrough Therapy status for severe hypertriglyceridemia. Learn what this means for trials, patients, and the RNAi market. byPallavi MadhirajuDecember 2, 2025